Novavax (NVAX) Shares Outstanding (Diluted Average) (2019 - 2025)
Novavax has reported Shares Outstanding (Diluted Average) over the past 7 years, most recently at $173.1 million for Q4 2025.
- Quarterly results put Shares Outstanding (Diluted Average) at $173.1 million for Q4 2025, up 13.74% from a year ago — trailing twelve months through Dec 2025 was $173.1 million (up 13.74% YoY), and the annual figure for FY2025 was $173.1 million, up 13.74%.
- Shares Outstanding (Diluted Average) for Q4 2025 was $173.1 million at Novavax, up from $162.4 million in the prior quarter.
- Over the last five years, Shares Outstanding (Diluted Average) for NVAX hit a ceiling of $177.6 million in Q1 2025 and a floor of $73.0 million in Q1 2021.
- Median Shares Outstanding (Diluted Average) over the past 5 years was $102.1 million (2023), compared with a mean of $114.1 million.
- Biggest five-year swings in Shares Outstanding (Diluted Average): increased 5.08% in 2022 and later soared 62.39% in 2024.
- Novavax's Shares Outstanding (Diluted Average) stood at $74.4 million in 2021, then rose by 5.08% to $78.2 million in 2022, then rose by 28.89% to $100.8 million in 2023, then surged by 51.03% to $152.2 million in 2024, then grew by 13.74% to $173.1 million in 2025.
- The last three reported values for Shares Outstanding (Diluted Average) were $173.1 million (Q4 2025), $162.4 million (Q3 2025), and $177.2 million (Q2 2025) per Business Quant data.